Reproductive Medicine, KK Women's and Children's Hospital, Singapore, Singapore.
Cancer and Stem Cell Biology Program, Duke-National University of Singapore (NUS) Medical School, Singapore.
FASEB J. 2019 Mar;33(3):3954-3967. doi: 10.1096/fj.201801391R. Epub 2018 Dec 5.
Adeno-associated viral vectors (AAVs) achieve stable therapeutic expression without long-term toxicity in adults with hemophilia. To avert irreversible complications in congenital disorders producing early pathogenesis, safety and efficacy of AAV-intrauterine gene transfer (IUGT) requires assessment. We therefore performed IUGT of AAV5 or -8 with liver-specific promoter-1 encoding either human coagulation factors IX (hFIX) or X (hFX) into Macaca fascicularis fetuses at ∼0.4 gestation. The initial cohort received 1 × 10 vector genomes (vgs) of AAV5-hFIX ( n = 5; 0.45 × 10 vg/kg birth weight), resulting in ∼3.0% hFIX at birth and 0.6-6.8% over 19-51 mo. The next cohort received 0.2-1 × 10 vg boluses. AAV5-hFX animals ( n = 3; 3.57 × 10 vg/kg) expressed <1% at birth and 9.4-27.9% up to 42 mo. AAV8-hFIX recipients ( n = 3; 2.56 × 10 vg/kg) established 4.2-41.3% expression perinatally and 9.8-25.3% over 46 mo. Expression with AAV8-hFX ( n = 6, 3.12 × 10 vg/kg) increased from <1% perinatally to 9.8-13.4% >35 mo. Low expressers (<1%, n = 3) were postnatally challenged with 2 × 10 vg/kg AAV5 resulting in 2.4-13.2% expression and demonstrating acquired tolerance. Linear amplification-mediated-PCR analysis demonstrated random integration of 57-88% of AAV sequences retrieved from hepatocytes with no events occurring in or near oncogenesis-associated genes. Thus, early-IUGT in macaques produces sustained curative expression related significantly to integrated AAV in the absence of clinical toxicity, supporting its therapeutic potential for early-onset monogenic disorders.-Chan, J. K. Y., Gil-Farina I., Johana, N., Rosales, C., Tan, Y. W., Ceiler, J., Mcintosh, J., Ogden, B., Waddington, S. N., Schmidt, M., Biswas, A., Choolani, M., Nathwani, A. C., Mattar, C. N. Z. Therapeutic expression of human clotting factors IX and X following adeno-associated viral vector-mediated intrauterine gene transfer in early-gestation fetal macaques.
腺相关病毒载体 (AAV) 在成人血友病患者中实现稳定的治疗性表达,而无长期毒性。为避免产生早期发病机制的先天性疾病的不可逆并发症,需要评估 AAV-宫内基因转移 (IUGT) 的安全性和疗效。因此,我们在大约 0.4 妊娠时将具有肝脏特异性启动子-1 的 AAV5 或-8 与编码人凝血因子 IX (hFIX) 或 X (hFX) 的载体转染到猕猴胎儿中。初始队列接受了 1×10 个 AAV5-hFIX 的载体基因组 (vgs) (n=5; 0.45×10 vg/kg 出生体重),导致出生时 hFIX 约为 3.0%,19-51 个月时为 0.6-6.8%。下一个队列接受了 0.2-1×10 vg 的 bolus。AAV5-hFX 动物 (n=3; 3.57×10 vg/kg) 在出生时表达<1%,42 个月时表达 9.4-27.9%。AAV8-hFIX 接受者 (n=3; 2.56×10 vg/kg) 在围产期建立了 4.2-41.3%的表达,46 个月时为 9.8-25.3%。AAV8-hFX (n=6, 3.12×10 vg/kg) 的表达从围产期的<1%增加到>35 个月时的 9.8-13.4%。低表达者(<1%,n=3)在出生后接受了 2×10 vg/kg AAV5 的挑战,导致 2.4-13.2%的表达,并表现出获得性耐受。线性扩增介导的-PCR 分析表明,从肝细胞中回收的 57-88%的 AAV 序列随机整合,没有发生在致癌相关基因内或附近。因此,在猕猴中早期 IUGT 产生的持续治疗性表达与整合的 AAV 显著相关,而无临床毒性,支持其用于治疗早发性单基因疾病的治疗潜力。-陈,J. K. Y.,吉尔-法里纳,I.,约翰娜,N.,罗萨莱斯,C.,谭,Y. W.,塞勒,J.,麦金托什,J.,奥格登,B.,沃丁顿,S. N.,施密特,M.,比斯瓦斯,A.,乔拉尼,M.,纳特瓦尼,A. C.,马塔尔,C. N. Z. 腺相关病毒载体介导的宫内基因转移在早期妊娠猕猴胎儿中治疗性表达人凝血因子 IX 和 X。